company background image
IMGN

ImmunoGen NasdaqGS:IMGN Stock Report

Last Price

US$4.75

Market Cap

US$1.0b

7D

1.9%

1Y

-15.9%

Updated

30 Jan, 2023

Data

Company Financials +

IMGN Stock Overview

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer.

IMGN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

ImmunoGen, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ImmunoGen
Historical stock prices
Current Share PriceUS$4.75
52 Week HighUS$6.63
52 Week LowUS$3.10
Beta0.89
1 Month Change-4.23%
3 Month Change-15.48%
1 Year Change-15.93%
3 Year Change1.50%
5 Year Change-44.31%
Change since IPO-42.42%

Recent News & Updates

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

Jan 03
What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

Recent updates

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

Jan 03
What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

New Forecasts: Here's What Analysts Think The Future Holds For ImmunoGen, Inc. (NASDAQ:IMGN)

Nov 17
New Forecasts: Here's What Analysts Think The Future Holds For ImmunoGen, Inc. (NASDAQ:IMGN)

We Think ImmunoGen (NASDAQ:IMGN) Needs To Drive Business Growth Carefully

Oct 17
We Think ImmunoGen (NASDAQ:IMGN) Needs To Drive Business Growth Carefully

We're Keeping An Eye On ImmunoGen's (NASDAQ:IMGN) Cash Burn Rate

Jul 03
We're Keeping An Eye On ImmunoGen's (NASDAQ:IMGN) Cash Burn Rate

Companies Like ImmunoGen (NASDAQ:IMGN) Are In A Position To Invest In Growth

Feb 27
Companies Like ImmunoGen (NASDAQ:IMGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About ImmunoGen's (NASDAQ:IMGN) Cash Burn Situation

Nov 13
Here's Why We're Not Too Worried About ImmunoGen's (NASDAQ:IMGN) Cash Burn Situation

Shareholders May Not Be So Generous With ImmunoGen, Inc.'s (NASDAQ:IMGN) CEO Compensation And Here's Why

Jun 10
Shareholders May Not Be So Generous With ImmunoGen, Inc.'s (NASDAQ:IMGN) CEO Compensation And Here's Why

Does ImmunoGen (NASDAQ:IMGN) Have A Healthy Balance Sheet?

Mar 13
Does ImmunoGen (NASDAQ:IMGN) Have A Healthy Balance Sheet?

Need To Know: Analysts Are Much More Bullish On ImmunoGen, Inc. (NASDAQ:IMGN) Revenues

Feb 15
Need To Know: Analysts Are Much More Bullish On ImmunoGen, Inc. (NASDAQ:IMGN) Revenues

Can You Imagine How ImmunoGen's (NASDAQ:IMGN) Shareholders Feel About The 48% Share Price Increase?

Jan 29
Can You Imagine How ImmunoGen's (NASDAQ:IMGN) Shareholders Feel About The 48% Share Price Increase?

How Much Of ImmunoGen, Inc. (NASDAQ:IMGN) Do Institutions Own?

Dec 07
How Much Of ImmunoGen, Inc. (NASDAQ:IMGN) Do Institutions Own?

Shareholder Returns

IMGNUS BiotechsUS Market
7D1.9%0.8%2.8%
1Y-15.9%7.1%-9.2%

Return vs Industry: IMGN underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: IMGN underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is IMGN's price volatile compared to industry and market?
IMGN volatility
IMGN Average Weekly Movement8.9%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: IMGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: IMGN's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1980106Mark Enyedyhttps://www.immunogen.com

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate.

ImmunoGen, Inc. Fundamentals Summary

How do ImmunoGen's earnings and revenue compare to its market cap?
IMGN fundamental statistics
Market CapUS$1.05b
Earnings (TTM)-US$201.09m
Revenue (TTM)US$95.61m

11.0x

P/S Ratio

-5.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMGN income statement (TTM)
RevenueUS$95.61m
Cost of RevenueUS$203.85m
Gross Profit-US$108.25m
Other ExpensesUS$92.85m
Earnings-US$201.09m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.91
Gross Margin-113.22%
Net Profit Margin-210.33%
Debt/Equity Ratio0%

How did IMGN perform over the long term?

See historical performance and comparison